Prospective randomized phase IV open label comparative study of dalteparin [fragmin] vs unfractionated heparin for the prevention of venous thromboembolism (VTE) in hospitalized acutely ill medical patients.

Trial Profile

Prospective randomized phase IV open label comparative study of dalteparin [fragmin] vs unfractionated heparin for the prevention of venous thromboembolism (VTE) in hospitalized acutely ill medical patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Dalteparin sodium; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Dec 2008 Planned number of patients changed from 360 to 84.
    • 25 Sep 2008 Study start date changed from Aug 2007 to Jul 2007 as reported by CT.gov
    • 25 Sep 2008 Status changed from recruiting to discontinued as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top